Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results
Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, including durable complete responses
Secured over $13 million in non-dilutive funding from the Cancer Prevention & Research Institute of Texas (CPRIT) and the National Institute of Health (NIH) Small Business Innovation Research (SBIR) to support pancreatic and lymphoma clinical programs
Approval from United States Adopted Name (USAN) council and International Nonproprietary Names $(INN)$ expert committee for "neldaleucel" as nonproprietary name for MT-601
Strategic financing to support clinical advancements to investigate MT-601 in patients with lymphoma
HOUSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced corporate updates and financial results for the year ended December 31, 2024.
"In 2024, we made substantial progress advancing MT-601, our lead multi antigen recognizing $(MAR)$-T cell therapy, and laid the groundwork for continued momentum in 2025," said Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics. "Preliminary data from our Phase 1 APOLLO study showed encouraging safety and efficacy results in lymphoma patients who relapsed after anti-CD19 CAR-T cell therapy. With a 78% objective response rate and favorable safety profile, we believe MT-601 has the potential to provide a transformative treatment option for this patient population. We look forward to sharing additional insights during a webinar in the second quarter of 2025."
"We also strengthened our financial position through a strategic private placement and additional non-dilutive funding from the NIH and CPRIT. As we move further into 2025, our focus remains on cash preservation and disciplined execution to maximize the impact of our clinical programs," concluded Dr. Vera.
2024 PROGRAM UPDATES & OPERATIONAL HIGHLIGHTS
MT-601 (Lymphoma)
-- MT-601, Marker's lead MAR-T cell therapy, is being evaluated in the
nationwide multicenter Phase 1 APOLLO study (clinicaltrials.gov
identifier: NCT05798897) in patients with anti-CD19 CAR-T relapsed
lymphoma or where CAR-T cells are not an option.
-- The Company provided an update on the APOLLO study (Press Release,
December 19, 2024). Key findings from the study include:
-- Safety: MT-601 was well tolerated across all study participants.
No immune-effector cell associated neurotoxicity syndrome (ICANS)
and one case of Grade 1 cytokine release syndrome $(CRS)$ were
observed. No dose limiting toxicities (DLTs) have been reported to
date.
-- Efficacy: In the first dose cohort, 7 out of 9 patients achieved
objective responses (78%) at first response assessment, with 4
patients demonstrating complete response (CR; 44.4%).
-- Time in Follow-Up: Three patients have been followed for 6 to 12
months, with ongoing follow-up underway. All study participants
are monitored closely to ensure comprehensive data collection and
patient safety.
-- The Company is enrolling additional study participants in the Phase 1
APOLLO trial and expects to report further data in the second half of
2025.
MT-601 (Pancreatic)
-- Marker received $2 million from NIH SBIR and $9.5 million from CPRIT to
support the development of MT-601 in metastatic pancreatic cancer.
-- Clinical program launch is anticipated in the second half of 2025.
MT-401-OTS (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
-- The Company previously secured non-dilutive funding to support the
clinical investigation of MT-401 as an "Off-the-Shelf" (MT-401-OTS)
product in patients with Acute Myeloid Leukemia $(AML.UK)$ or Myelodysplastic
Syndrome (MDS). MT-401-OTS is manufactured from healthy donors and a
cellular inventory has been established with ongoing efforts to expand.
-- The Company anticipates clinical program initiation during the second
half of 2025.
2024 CORPORATE HIGHLIGHTS
-- Announced clinical pipeline prioritization in January 2024 to
strategically focus on MT-601 in patients with lymphoma. This
announcement also included program updates that highlighted the potential
of the Company's MT-401-OTS program for patients with AML (Press Release,
January 8, 2024).
-- The United States Adopted Names (USAN) and International Nonproprietary
Names (INN) committees approved "neldaleucel" as the nonproprietary
(generic) name for MT-601.
-- On December 23, 2024, the Company announced a $16.1 million private
placement to support the clinical advancements of the Phase 1 APOLLO
study. The financing involved participation from new and existing
investors, including esteemed firms such as Blue Owl, New Enterprise
Associates $(NEA)$ and Aisling Capital.
FISCAL YEAR 2024 FINANCIAL HIGHLIGHTS
Cash Position and Guidance: At December 31, 2024, Marker had cash and cash equivalents of $19.2 million. The Company believes that its existing cash and cash equivalents will fund its operating expenses into the first quarter of 2026, assuming no additional grant funds are received. We anticipate receiving additional grant funding, which we expect could extend our runway beyond Q1 2026.
R&D Expenses: Research and development expenses were $13.5 million for the year ended December 31, 2024, compared to $10.4 million for the year ended December 31, 2023.
G&A Expenses: General and administrative expenses were $4.2 million for the year ended December 31, 2024, compared to $7.5 million for the year ended December 31, 2023.
Net Loss: Marker reported a net loss of $10.7 million for the year ended December 31, 2024, compared to a net loss of $8.2 million for the year ended December 31, 2023.
About MAR-T cells
The multi-antigen recognizing $(MAR.AU)$ T cell platform (formerly known as multiTAA-specific T cells) is a novel, non-genetically modified cell therapy approach that selectively expands tumor-specific T cells from a patient's/donor's blood capable of recognizing a broad range of tumor antigens. Unlike other T cell therapies, MAR-T cells allow the recognition of hundreds of different epitopes within up to six tumor-specific antigens, thereby reducing the possibility of tumor escape. Since MAR-T cells are not genetically engineered, Marker believes that its product candidates will be easier and less expensive to manufacture, with an improved safety profile compared to current engineered T cell approaches, and may provide patients with meaningful clinical benefits.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a Houston, TX-based clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. The Company was founded at Baylor College of Medicine, and clinical trials that enrolled more than 200 patients across various hematological and solid tumor indications showed that the Company's autologous and allogeneic MAR-T cell products were well tolerated and demonstrated durable clinical responses. Marker's goal is to introduce novel T cell therapies to the market and improve patient outcomes. To achieve these objectives, the Company prioritizes the preservation of financial resources and focuses on operational excellence. Marker's unique T cell platform is strengthened by non-dilutive funding from U.S. state and federal agencies supporting cancer research.
To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.
Forward-Looking Statements
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the timing, conduct, interim results announcements and outcomes of our clinical trials of our product candidates, including MT 601 for the treatment of patients with lymphoma. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at WWW.SEC.GOV. The Company assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release except as may be required by law.
Marker Therapeutics, Inc.
Consolidated Balance Sheets
(Audited)
December 31, December 31,
2024 2023
ASSETS
Current assets:
Cash and cash equivalents $ 19,192,440 $ 15,111,450
Prepaid expenses and deposits 483,717 988,126
Other receivables 2,346,703 1,027,815
Total current assets 22,022,860 17,127,391
Total assets $ 22,022,860 $ 17,127,391
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued
liabilities $ 1,753,954 $ 1,745,193
Related party payable 1,710,500 1,329,655
Total current liabilities 3,464,454 3,074,848
Total liabilities 3,464,454 3,074,848
------------ ------------
Stockholders' equity:
Preferred stock, $0.001 par
value, 5 million shares
authorized, 0 shares issued and
outstanding at December 31, 2024
and 2023, respectively - -
Common stock, $0.001 par value,
30 million shares authorized,
10.7 million and 8.9 million
shares issued and outstanding
as of December 31, 2024 and
2023, respectively (see Note
8) 10,708 8,891
Additional paid-in capital 465,564,876 450,329,515
Accumulated deficit (447,017,178) (436,285,863)
------------ ------------
Total stockholders' equity 18,558,406 14,052,543
------------ ------------
Total liabilities and stockholders'
equity $ 22,022,860 $ 17,127,391
============ ============
Marker Therapeutics, Inc.
Consolidated Statements of Operations
(Audited)
For the Year Ended
December 31,
------------------------------
2024 2023
Revenues:
Grant income $ 6,591,080 $ 3,311,133
Total revenues 6,591,080 3,311,133
----------- -----------
Operating expenses:
Research and development 13,467,845 10,416,789
General and administrative 4,241,607 7,475,722
----------- -----------
Total operating expenses 17,709,452 17,892,511
Loss from operations (11,118,372) (14,581,378)
Other income (expenses):
Interest income 437,010 539,158
----------- -----------
Loss from continuing operations before
income taxes (10,681,362) (14,042,220)
----------- -----------
Income tax expense 49,953 3,675
Net loss from continuing operations (10,731,315) (14,045,895)
Discontinued operations:
Loss from discontinued operations,
net of tax - (2,922,406)
Gain on disposal of discontinued
operations - 8,731,487
Income from discontinued operations - 5,809,081
----------- -----------
Net loss $(10,731,315) $ (8,236,814)
=========== ===========
Net loss per share:
Loss from continuing operations,
basic and diluted $ (1.19) $ (1.59)
=========== ===========
Income from discontinued
operations, basic and diluted $ - $ 0.66
=========== ===========
Net loss per share, basic and
diluted $ (1.19) $ (0.94)
=========== ===========
Weighted average number of common
shares outstanding:
Basic 8,980,207 8,809,382
=========== ===========
Diluted 8,980,207 8,809,382
=========== ===========
Marker Therapeutics, Inc.
Consolidated Statements of Cash Flows
(Audited)
For the Year Ended
December 31,
------------------------------
2024 2023
Cash Flows from Operating Activities:
Net loss $(10,731,315) $ (8,236,814)
Less: gain from discontinued
operations, net of tax - 5,809,081
Net loss from continuing operations (10,731,315) (14,045,895)
Reconciliation of net loss to net
cash used in operating activities:
Stock-based compensation 245,864 858,269
Changes in operating assets and
liabilities:
Prepaid expenses and deposits 504,409 861,113
Other receivables (1,318,888) 1,374,189
Related party payable 380,845 1,329,655
Accounts payable and accrued
expenses 8,761 (718,393)
Net cash used in operating
activities - continuing
operations (10,910,324) (10,341,062)
Net cash used in operating
activities - discontinued
operations - (6,098,899)
----------- -----------
Net cash used in operating
activities (10,910,324) (16,439,961)
Cash Flows from Investing Activities:
Net cash provided by investing
activities - discontinued
operations - 18,664,122
Net cash provided by investing
activities - 18,664,122
----------- -----------
Cash Flows from Financing Activities:
Proceeds from issuance of common
stock, net 14,929,155 1,014,640
Proceeds from stock options
exercise 62,159 90,477
Net cash provided by financing
activities 14,991,314 1,105,117
Net increase in cash and cash
equivalents 4,080,990 3,329,278
Cash and cash equivalents at beginning
of the period 15,111,450 11,782,172
----------- -----------
Cash and cash equivalents at end of
the period $ 19,192,440 $ 15,111,450
=========== ===========
Media and Investor Contact
Marker Therapeutics, Inc.
+1 (713) 400-6400
investor.relations@markertherapeutics.com
(END) Dow Jones Newswires
March 31, 2025 08:45 ET (12:45 GMT)
